Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.81 |
| ▸ | DRD2 | P14416 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.81 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | HTR1A | P08908 | 1/20 | 0.81 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.81 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.81 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.81 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.81 |
| ▸ | DRD1 | P21728 | 1/20 | 0.81 |
| ▸ | DRD4 | P21917 | 1/20 | 0.81 |
| ▸ | HRH2 | P25021 | 1/20 | 0.81 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.81 |
| ▸ | HTR2A | P28223 | 1/20 | 0.81 |
| ▸ | HTR2C | P28335 | 1/20 | 0.81 |
| ▸ | HTR7 | P34969 | 1/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549271 | 1.00 | ADRA2A (0.81) | ADRA2ADRD2LMNACHRM2CHRM4 | |
| SCHEMBL12260186 | 0.92 | DRD2 (0.81) | ADRA2ADRD2LMNACHRM2CHRM4 | |
| SCHEMBL17509819 | 0.91 | DRD2 (0.67) | ADRA2ADRD2LMNACHRM2CHRM4 | |
| SCHEMBL20959758 | 0.90 | CHRM1 (0.66) | ADRA2ADRD2LMNACHRM2CHRM4 | |
| Quetiapine SCHEMBL29360153 | 0.90 | DRD2 (1.00) | ADRA2ADRD2LMNACHRM2CHRM4 | |
| Quetiapine SCHEMBL4283801 | 0.90 | DRD2 (1.00) | ADRA2ADRD2LMNACHRM2CHRM4 | |
| Quetiapine SCHEMBL4638768 | 0.90 | DRD2 (1.00) | ADRA2ADRD2LMNACHRM2CHRM4 | |
| Quetiapine SCHEMBL7932 | 0.90 | DRD2 (1.00) | ADRA2ADRD2LMNACHRM2CHRM4 | |
| SCHEMBL2615342 | 0.89 | DRD2 (0.80) | ADRA2ADRD2LMNACHRM2CHRM4 | |
| Quetiapine SCHEMBL392703 | 0.89 | DRD2 (0.98) | ADRA2ADRD2LMNACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052648-A1 | ORAL MODIFIED-RELEASE FORMULATIONS CONTAINING THIAZEPINES | AVRAMOFF AVI | 2011-03-03 | — | — | US | claimed |
| US-10010615-B2 | Amino acid conjugates of quetiapine, process for making and using the same | KEMPHARM, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170246308-A1 | Amino Acid Conjugates of Quetiapine, Process for Making and Using the Same | ALTER DOMUS (US) LLC | 2017-08-31 | — | — | US | disclosed |
| US-20170246307-A1 | Amino Acid Conjugates of Quetiapine, Process for Making and Using the Same | ALTER DOMUS (US) LLC | 2017-08-31 | — | — | US | disclosed |
| US-20170209586-A1 | AMINO ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME | ALTER DOMUS (US) LLC | 2017-07-27 | — | — | US | disclosed |
| US-9597403-B2 | Amino acid conjugates of quetiapine, process for making and using the same | KEMPHARM, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2987789-A1 | AMINO ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2519101-B1 | AMINO ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME | KEMPHARM INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20140287050-A1 | AMINO ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8715699-B2 | Amino acid conjugates of quetiapine, process for making and using the same | KEMPHARM, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INCORPORATED | 2005-09-01 | — | — | US | disclosed |
| US-20050187200-A1 | Methods and reagents for the treatment of inflammatory disorders | COMBINATORX, INCORPORATED | 2005-08-25 | — | — | US | disclosed |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005048927-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050112199-A1 | Therapeutic regimens for administering drug combinations | COMBINATORX, INCORPORATED | 2005-05-26 | — | — | US | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005030132-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187200-A1 | Methods and reagents for the treatment of inflammatory disorders | IL5, TNF, LTC4S | ADRA2A 2053/4885DRD2 3820/4885LMNA 2007/4885 |
| US-20170246307-A1 | Amino Acid Conjugates of Quetiapine, Process for Making and Using the Same | QPCT, SLC1A5, SLC1A2 | ADRA2A 912/4885DRD2 159/4885LMNA 2684/4885 |
| US-20170209586-A1 | AMINO ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME | QPCT, AADAT, SLC1A5 | ADRA2A 1254/4885DRD2 224/4885LMNA 1914/4885 |
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, CMA1, CCL11 | ADRA2A 831/4885DRD2 2151/4885LMNA 3952/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | ADRA2A 2769/4885DRD2 3053/4885LMNA 4062/4885 |
| US-20170246308-A1 | Amino Acid Conjugates of Quetiapine, Process for Making and Using the Same | QPCT, SLC1A5, SLC1A2 | ADRA2A 912/4885DRD2 159/4885LMNA 2684/4885 |
| US-20140287050-A1 | AMINO ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME | QPCT, SLC1A5, SLC1A2 | ADRA2A 1076/4885DRD2 176/4885LMNA 2729/4885 |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | ADRA2A 4163/4885DRD2 4506/4885LMNA 3888/4885 |
| US-10010615-B2 | Amino acid conjugates of quetiapine, process for making and using the same | QPCT, SLC1A5, SLC1A2 | ADRA2A 912/4885DRD2 159/4885LMNA 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.